Epcoritamab in Combination With Loncastuximab Tesirine in Relapsed/Refractory Large B-cell Lymphoma
Status:
NOT_YET_RECRUITING
Trial end date:
2030-12-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine whether combining Loncastuximab Tesirine with Epcoritamab is tolerable and effective for reducing and/or eliminating lymphoma cells in the body.